UBS and Citi Go Bullish on Gilead Sciences (GILD)

Core Viewpoint - Gilead Sciences, Inc. (NASDAQ:GILD) is considered one of the most undervalued blue chip stocks currently available for investment [1] Analyst Upgrades - UBS analyst Michael Yee upgraded Gilead's stock from 'Neutral' to 'Buy' and raised the price target from $112 to $145, citing strong expectations for HIV pre-exposure prophylaxis sales from Yeztugo [2] - Citi analyst Geoff Meacham also raised the price target from $135 to $140 while maintaining a 'Buy' rating, reflecting growing confidence in Gilead's outlook [3] Strategic Developments - Gilead exercised its option to exclusively license Assembly Biosciences' long-acting HSV helicase-primase inhibitor programs, ABI-1179 and ABI-5366, which aims to expand its antiviral pipeline into areas with significant unmet needs [4] - The licensing deal is supported by positive Phase 1b data and the potential for once-weekly oral dosing, indicating a strategic evolution towards more durable, growth-oriented demand drivers in the antiviral sector [4] Company Focus - Gilead Sciences, Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative medicines across various therapeutic areas, including HIV, liver disease, oncology, hematology, and inflammatory conditions [5]